Company Overview of Glaxosmithkline Biologicals S.A.
Glaxosmithkline Biologicals S.A. researches, develops, manufactures, and supplies vaccines. Its vaccination products are used to tackle various diseases, such as rabies, diphtheria, tetanus, and yellow fever, as well as polio, measles, mumps, and rubella and hepatitis B. Glaxosmithkline Biologicals S.A. was formerly known as SmithKline Beecham Biologicals S.A. and changed its name to GlaxoSmithKline Biologicals S.A. in 2000. The company was founded in 1945 and is based in Rixensart, Belgium. Glaxosmithkline Biologicals S.A. operates as a subsidiary of GlaxoSmithKline plc.
Rue de l'institut 89
Founded in 1945
32 2 656 81 11
32 2 656 80 00
Key Executives for Glaxosmithkline Biologicals S.A.
Chief Executive of GlaxoSmithKline PLC
Compensation as of Fiscal Year 2014.
Glaxosmithkline Biologicals S.A. Key Developments
Arabio Signs Agreement with GSK for Local Production of Vaccines
Mar 18 14
GSK Vaccines and Glaxo Saudi Arabia Limited (GSAL) have signed an agreement with ARABIO under which a number of vaccines will be manufactured in Saudi Arabia. The vaccines to be manufactured locally include Infanrix hexa - used in the prevention of Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and Haemophilus influenzae type b (Hib) - and Rotarix - used in the prevention of symptoms caused by rotavirus infection. Under the agreement, GSK Vaccines will transfer knowledge related to the vaccines to GSAL and ARABIO.
GSK Vaccines Presents at EBD Group's 7th Annual BIO-Europe Spring Conference 2013, Mar-11-2013
Feb 7 13
GSK Vaccines Presents at EBD Group's 7th Annual BIO-Europe Spring Conference 2013, Mar-11-2013 . Venue: Centre Covencions International Barcelona, Plaça de Willy Brandt, 11-14, 08019 Barcelona, Spain.
GlycoVaxyn AG and GlaxoSmithKline Biologicals Sign Bacterial Vaccine Development Partnership
Dec 20 12
GlycoVaxyn and GlaxoSmithKline Biologicals (GSK) have signed a research partnership for the development of new bacterial vaccines. The collaboration, planned for three years, will leverage GlycoVaxyn's bio-conjugation technology in developing vaccines against a range of undisclosed bacterial pathogens. As per the deal, GlycoVaxyn will obtain an upfront payment along with an equity investment in addition to milestone payments and royalties on licensed candidates. During the collaboration, GSK has an option to acquire exclusive license on the vaccine targets, extend the period of collaboration and expand the capacity of the partnership.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|